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A B S T R A C T
Although there is no routine procedure for determination of serum markers in patients with malignant melanoma
(MM), some markers are being studied as potentially useful prognostic tools. Serum lactate dehydrogenase (LDH), pro-
tein S-100B, melanoma-inhibiting activity (MIA) and tyrosinase may correlate with melanoma progression. In this
study, the results of determination of S100 protein, LDH, MIA and tyrosinase in the serum of 50 patients with MM
(stages I-IV) were determined. The increased values of MIA were found in 26% patients in stage I, while in 50% patients
in stage IV. Increased S-100 protein was found in 13% patients in stage I while in 50% patients in stage IV. The increased
values of LDH were found in 26% patients in stage I, while in 25% patients in stage IV. The positive serum tyrosinase was
noticed in 17.3% patients in stage II, while in 25% patients in stage IV. The obtained results have revealed no significant
differences between the groups in higher and lower stages of the disease, indicating that blood markers are not reliable
prognostic factors for MM progression.
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Introduction
The serum markers in patients with malignant tu-
mours, including malignant melanoma (MM), may be
valuable in clinical diagnosis, prognosis and monitoring
of the disease and patients' response to therapy over
time. The research data so far pointed out few blood
markers as promising prognostic parameters in the de-
tection of tumour progression. The most widely used se-
rum markers are S-100, melanoma inhibitory activity
(MIA), and lactate dehydrogenase (LDH). Different stud-
ies indicated close correlations between the serum con-
centrations of these and tumour load1,2. Increased serum
concentrations of these marker proteins being indicative
of tumour growth3,4, but they still cannot be used as an
evidence of tumour progression. Until now there is no
marker available to detect metastatic spread at an early
stage in the progression of the disease. Laboratory tests
and imaging procedures increase the probability of de-
tecting occult metastases. The current treatment recom-
mendations for the patients with MM, comprise various
clinical and radiological examinations according to the
stage of the disease (including chest x-rays, ultrasound of
lymph nodes and abdomen, CT-, MRI- and PET scans).
However, there is no unique consensus in clinical prac-
tice5. Besides LDH, which is a leading blood parameter in
patients with melanoma metastases, there are two se-
rum proteins widely used in the follow-up of patients
with MM; protein S-100 , a member of the S-100 protein
family, and melanoma-inhibiting activity (MIA), which is
a soluble protein6. Increased levels of LDH in serum of
melanoma patients were detected in 1954. Ever since the
value of LDH as a tumour marker for MM has been dis-
cussed. LDH was reported to be an indicator for liver
metastases, with high sensitivity and a specifity5,7. Mela-
noma-inhibiting activity (MIA) is strongly expressed by
malignant melanocytes while naevi show only moderate,
low or no expression1,2. The mature protein consists of
107 amino acids; its molecular weight is approximately
11 kd. MIA especially inhibits the attachment of mela-
noma cells to fibronectin and laminin, which leads to an
increasing motility. Melanoma cells and mature chondro-
cytes express MIA whilst low levels of MIA-mRNA are
found in various other cell types. In malignant tumours,
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high MIA mRNA levels were detected in almost 100% of
MM samples. S-100 protein is an acid calcium-binding
protein with a molecular weight of 21kd found in the ner-
vous system of vertebrates. Its name derives from its sol-
ubility in 100% saturated ammonium sulphate at neutral
pH. It is dimerous protein, consisting of two isomerous
subunits;  (MW 10.4 kd) and  (MW 10.5 kd), whereby
each of the possible combinations occurs. S-100 has
been found in melanoma cells and is used for the immu-
nohistochemical diagnosis of amelanotic melanomas. In
the recent literature, serum S-100 was suggested as a se-
rum marker for staging and monitoring therapy of pa-
tients with MM1,2. It has been indicated that levels of
S-100 as well as of MIA in peripheral blood, correlate
with melanoma progression, demonstrating a higher
sensitivity, specificity, and diagnostic accuracy then other
parameters in the diagnosis of newly occurring mela-
noma metastasis1,8. Tyrosinase and tyrosinase-related
protein-1 are enzymes involved in melanin synthesis and
are specific to melanocytes and melanoma cells. Tyrosi-
nase catalyses the oxidation of tyrosine to dopa and fur-
ther to dopaquinone. Expression of the tyrosinase is con-
fined to cells of the melanocitic lineage and Schwann
cells. Determination of the serum concentration of tyro-
sinase may also be important marker in patients with
MM. The aim of this study was to determine and com-
pare levels of MIA, S-100 protein, LDH, and tyrosinase
in the serum of patients with MM in different stages of
disease, as well as to conclude whether these might be
useful prognostic tools for MM progression.
Materials and Methods
In the present study, serum levels of MIA, S-100 pro-
tein, LDH, and tyrosinase were measured over a time pe-
riod from 2002 to 2006. The markers in serum samples
from 50 melanoma patients at different stages of disease
were analyzed (Table 1).
Diagnosis of MM was based on the histopathological
examination of the surgically removed lesions. Tumour
thickness was determined according to the criteria of
Breslow and tumour stage according to the TNM classifi-
cation. Clasification of the MM stages was based on
UICC (according to Hermanek et al., 1987): T, N, M sys-
tem: Stage I: T1-2, N0, M0; Stage II: T3-4, N0, M0; Stage
III: T1-4, N1-2, M0; Stage IV: T1-4, N1-2, M15. The fol-
lowing classification of the stages was used: I: (a) 0–0.75,
(b) 0.76–1.5 mm; II: (a) 1.51–4.00 mm, (b) >4.00 mm; III:
T1-4, N1, N2 (regional lymph nodes), M0; IV: T1-4, N1-2,
M1 (distant metastases).
In our study 50 patients were included; 26 females
and 24 males, aged from 22 to 83 (Figure 1). There were
15 patients in stage I; 23 in stage II; 8 in stage III, and 4
in stage IV of the disease. Serum concentrations of MIA
were measured by enzyme-linked immunosorbent assays
(ELISA), Photometric Enzyme Linked Immunosorbent
Assay (Dia Sarin), (n.v.<10 ng/mL). Serum concentra-
tions of S-100 were determined by Sangtec 100 ELISA
(n.v.<0.150  g/L). Serum concentrations of LDH were
measured by UV assay (n.v.<241 U/L). Serum concentra-
tions of tyrosinase were measured by RT – PCR (n.v.=
negative).
Results
The results of the serum markers analysis are pre-
sented in the figures 1–5. The increased values of MIA
were noticed in 26% of the patients in stage I, in 26% in
stage II, in 0% in stage III and, in 50% in stage IV (Figure
2). The increased values of S-100 protein were found in
13% of the patients in stage I, in 9% in stage II, in 0% in
stage III and, in 50% in stage IV (Figure 3). The in-
creased vaules of LDH were noticed in 26% of the pa-
tients in stage I, in 4% stage II, 13% in stage III and, in
25% in stage IV (Figure 4). The positive serum tyrosinase
was found in 0% of the patients in stage I, in 17.3% in
stage II, in 12.5% in stage III and, in 25% in stage IV
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TABLE 1
PATIENTS WITH MM: CHARACTERISTICS
STAGE I n=15 (6 m : 9 f)
/age 17–71/ L: trunk 10, legs 3, arms 2
STAGE II n=23 (10 m : 13 f)
/age 22–71/ L: trunk 11, arms 6, legs 6
STAGE III n=8 (8 m : 3 f)
/age 45–74/ L: trunk 4, legs 3, arms 1
STAGE IV n=4 (3 m : 1 f)
/age 42–66/ L: trunk 4






Fig. 1. The groups of patients with malignant melanoma
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Fig. 2. The groups of patients with malignant melanoma
according to MIA values and stages (I-IV).
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(Figure 5). The majority of MM patients had values of
serum markers within the normal range.There was no
significant difference in the number of elevated serum
markers between the patients in the stage I, II, III or IV.
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Fig. 3. The groups of patients with malignant melanoma





















Fig. 4. The groups of patients with malignant melanoma
according to S-100 protein and stages.
Fig. 5. The groups of patients with malignant melanoma
























Fig. 6. The groups of patients with malignant melanoma
according to tyrosinase and stages.
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Discussion
Although there is no routine procedure for determi-
nation of serum tumour markers for the patients with
MM, some markers may have a significant role in the fol-
low-up, as possible prognostic factors in the early detec-
tion of disease progression or in the prediction of the
therapy outcome4. Serum protein S-100 and MIA have
been described as possible useful tumour markers for
MM. For most of these markers, serum levels are more
pronounced in more advanced stages of the disease.
Therefore, these markers seem to have no place in the
early detection of melanoma. On the other hand, sensi-
tivity in the advanced stages of disease seems to be
<100%, compromising their use as a new staging proce-
dure. MIA was found to be more sensitive as a potential
prognostic marker for patients with metastatic MM in
comparison with S-1005. Regular determination of S-100
and MIA levels during follow-up can be used for early de-
tection of the tumour relapse in melanoma patients, in-
creased serum concentrations of these marker proteins
being indicative of tumour growth9.
In our study, increased MIA level was found in 26% of
the patients in stage I (localized disease), in none of the
patients in stage III and, in only 50% of the patients with
visceral metastases. Furthermore, increased S-100 level
was found in only 50% of the patients with metastatic
disease. These findings indicate that increased levels of
both MIA and S-100 protein should not be considered
confident markers of the tumour dissemination. It has
been observed that patients with distant melanoma me-
tastases with elevated serum S-100, MIA, or LDH had
poorer overall survival than patients with normal serum
concentrations3,8. These three markers can also be used
to monitor the course of the disease and therapy outcome
in patients with distant metastases. Regular determina-
tion of S-100 and MIA levels during follow-up may be
used for early detection of a tumour relapse in melanoma
patients10,11. Thus increased serum concentrations of
these marker proteins may be indicative of tumour
growth. Auge et al. found the relation between S-100 and
metastases site with higher sensitivity and mean concen-
trations in patients with brain metastases with the low-
est in those with lung metastases1. They found the corre-
lation between MIA and the same metastases locations
and considered that S100 and MIA are useful markers
related to prognostic factors, being more effective when
used in combination. Krahn et al. suggested that S-100 is
a more reliable tumour marker in peripheral blood for
patients with newly occurred melanoma metastases com-
pared with MIA, albumin and LDH7. However, we found
increased level of LDH similar in patients with both lo-
calized (26%) and disseminated disease (25%). Regarding
to the given results, serum LDH in patients with MM
should not be considered a strongly reliable indicator of
the metastases occurrence. Since there are no marker
proteins for melanoma that are not dependent on the tu-
mour load, it is not currently possible to forecast the sur-
vival of patients who are tumour free after surgery12.
However, the serum markers currently available for mel-
anoma have only limited clinical use.
Conclusion
Serum markers are not suitable for screening or the
diagnostics of primary melanomas, but may be useful in
detection of metastatic spread at an early stage of MM
progression. The serum S-100 and MIA represent mark-
ers that may be valuable in metastases detection, tumour
progression monitoring, or in the prediction of the ther-
apy outcome. Thus, determination of serum markers in
MM patients may be used in practice and indicate a
widely disseminated incurable disease, but their use as
tumour markers for melanoma is limited.
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REZULTATI MJERENJA SERUMSKIH MARKERA U BOLESNIKA S MALIGNIM MELANOMOM
S A @ E T A K
Unato~ ~injenici da danas jo{ ne postoje to~ne smjernice za odabir serumskih markera u bolesnika s malignim mela-
nomom (MM), odre|eni markeri mogli bi imati zna~ajnu ulogu. Pokazalo se da razine laktat-dehidrogenaze (LDH),
proteina S-100B, MIA (melanoma-inchibiting activity), kao i tirozinaze mogu korelirati s progresijom melanoma. U
ovoj studiji navedeni pokazatelji mjereni su u 50 bolesnika s MM (stadij I-IV). Povi{ena razina MIA zabilje`ena je u 26%
bolesnika sa stadijem I, te u 50% bolesnika sa stadijem IV. Povi{ena razina S-100 proteina zabilje`ena je u 13% bo-
lesnika sa stadijem I, te u 25% bolesnika sa stadijem IV. Povi{ena razina LDH na|ena je u 26% bolesnika sa stadijem I,
te u 25% bolesnika sa stadijem IV. Pozitivna tirozinaza detektirana je u 17,3% bolesnika sa stadijem II, te u 25% bo-
lesnika sa stadijem IV. Zabilje`eni rezultati nisu otkrili statisti~ki zna~ajnu razliku izme|u skupina bolesnika sa ni`im,
odnosno vi{im stadijem bolesti, ukazuju}i na to da serumski markeri nisu pouzdani pokazatelji progresije MM.
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